Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumicitabine in infants with RSV
NCT02202356Phase 1Completed
- Sponsor
- Alios BioPharma
- Start
- Jul 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 1, randomised, double-blind trial of lumicitabine in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Alios BioPharma. Primary endpoints: Adverse Events, Physical Examinations and 3 more. Started Jul 2014; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02202356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202356.